551sek
1,5 %
Date:2025-06-04Time:18:00:00Latest report:Q1-2025List:First NorthTicker:ONCOZ
Market Cap:65 msekEnterprise Value:63 msekNet Sales:2,71 msekEarnings:-6,27 msekEmployees:0ISIN:SE0015504097

Ratios

10-year key figure history for OncoZenge turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for OncoZenge with index and moving average MA50 and MA200.

Stockprice:5,51
MA50:5,01
MA200:5,92
Price/MA200:-6,9 %
RSI (14):60,0
Price/MA50:10,0 %

Description

OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Pharmaceuticals